According to Taipei Biotech (6589), October revenue reached 270 million TWD, up 287.88% year-over-year, with cumulative revenue for the first 10 months of 2026 reaching 1.38 billion TWD, up 94.7% annually. The biotech firm attributed growth to CDMO contract manufacturing services and biosimilar drug royalty income. EG1206A has submitted marketing authorization applications to the European Medicines Agency as of late October, with filings planned to the FDA and Canadian Health Authority by year-end, targeting 2027 European and 2028 U.S. commercial launches. CEO Liu Li-cheng expects operational improvements and profitability restructuring from H2 2027 onward, driven by milestone royalties, post-launch sales splits, and expanding CDMO orders.

View Source

Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.